Globus Medical (GMED) Projected to Post Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Globus Medical Stock Performance

NYSE:GMED opened at $88.05 on Tuesday. The company has a market cap of $11.78 billion, a P/E ratio of 28.40, a P/E/G ratio of 1.35 and a beta of 1.06. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The stock’s 50-day simple moving average is $89.66 and its 200 day simple moving average is $74.29.

Insiders Place Their Bets

In other Globus Medical news, SVP Kelly Huller sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the transaction, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 31,636 shares of company stock worth $2,909,333. 18.54% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in shares of Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after purchasing an additional 7,086 shares during the period. Integrated Wealth Concepts LLC raised its holdings in shares of Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after buying an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Globus Medical by 38.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock valued at $2,228,000 after acquiring an additional 8,540 shares during the period. Jones Financial Companies Lllp raised its position in Globus Medical by 237.3% during the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after purchasing an additional 598 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Globus Medical by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after buying an additional 28,027 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Piper Sandler reiterated an “overweight” rating and issued a $115.00 price target (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Canaccord Genuity Group raised their price objective on Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Citigroup reiterated a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Finally, Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.18.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.